OncoNano Medicine Announces Martin Driscoll as CEO
Mr. Driscoll’s deep experience in the biopharmaceutical industry particularly the immuneoncology field makes him ideally suited to assume the leadership of OncoNano Medicine
SOUTHLAKE, TX – February 1, 2021 – OncoNano Medicine, Inc. today announced the appointment of Martin Driscoll as Chief Executive Officer and a member of the company’s Board of Directors. An accomplished industry veteran with multiple decades of biopharmaceutical development and commercialization experience, Mr. Driscoll most recently served as President and Chief Executive Officer of Spring Bank Pharmaceuticals. Mr. Driscoll succeeds co-founder and CEO Ravi Srinivasan, Ph.D., who has stepped down in a planned transition to pursue other interests.
“We are thrilled to welcome Marty to our team. Marty’s extensive experience and proven track record at the helm of several successful biopharmaceutical development companies will undoubtedly provide OncoNano with the leadership to advance our business and translate our novel discoveries into important new interventions and treatments for cancer patients,” said Al Guillem, Ph.D., Chairman of OncoNano. “Marty joins OncoNano at an important time as we progress our lead program into the pivotal trial stage and advance our first oncology therapeutic, ONM-501, towards the first human studies for this novel immuno-modulator.” Dr. Guillem continued, “On behalf of the OncoNano board of directors, I want to thank Ravi for his many contributions to the growth of our company and wish him great success in his future endeavors.”
“I’m joining OncoNano at an exciting point in the evolution of the company and I look forward to building on the strong foundation established by Ravi and the OncoNano team as we advance the clinical development of our impressive portfolio of differentiated programs,” said Mr.Driscoll. “I was attracted to this opportunity to lead OncoNano by the exciting potential for the company’s innovative core technology that exploits the universal pH biomarker of solid tumors to enhance real-time surgical imaging and enable more efficient and effective delivery of cancer treatments.”
Mr. Driscoll brings a proven record in leading privately-held and publicly-traded biopharmaceutical development and commercial-stage companies. He has been involved with or led the commercialization of several important therapies, the direct negotiation of numerous licensing and M&A transactions, multiple private and public capital fundraising efforts and the successful submission of major global product regulatory filings. Mr. Driscoll has also served as a director on the boards of eight biopharmaceutical and diagnostic companies during his career.
About OncoNano Medicine
OncoNano Medicine is developing a new class of products that exploit pH as a biomarker to diagnose and treat cancer with high specificity. Our product candidates are designed to help patients across the continuum of cancer care and include solid tumor therapeutics, agents for real-time image-guided surgery and a platform of product candidates that activate and guide the body’s immune system to target cancer. Learn more at www.OncoNano.com.
Contacts
Lauren Arnold
MacDougall
larnold@macbiocom.com
781-235-3060
